Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News iBio Inc IBIO

Healthcare Biotechnology
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies... see more

Recent & Breaking News (NDAQ:IBIO)

iBio to Participate in the 8th Annual Evercore Healthcare Conference

GlobeNewswire 12 days ago

iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update

GlobeNewswire November 12, 2025

iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance

GlobeNewswire October 30, 2025

iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

GlobeNewswire October 23, 2025

iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025

GlobeNewswire October 21, 2025

iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

GlobeNewswire September 5, 2025

iBio Announces Closing of $50 Million Public Offering

GlobeNewswire August 25, 2025

iBio Announces Pricing of $50 Million Public Offering

GlobeNewswire August 19, 2025

iBio Announces Proposed Public Offering

GlobeNewswire August 18, 2025

iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

GlobeNewswire June 24, 2025

iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

GlobeNewswire June 23, 2025

iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

GlobeNewswire June 16, 2025

iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

GlobeNewswire May 5, 2025

iBio Reports Fiscal Third Quarter 2025 Financial Results

GlobeNewswire May 2, 2025

iBio Raises $6.2 Million Through Warrant Inducement Transaction

GlobeNewswire April 29, 2025

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

GlobeNewswire April 22, 2025

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

GlobeNewswire April 7, 2025

iBio to Begin Trading on the Nasdaq Stock Exchange

GlobeNewswire February 19, 2025

iBio Reports Fiscal Second Quarter 2025 Financial Results

GlobeNewswire February 10, 2025

iBio Announces New Investments from Board Members and Officers

GlobeNewswire January 13, 2025